CytoDyn (OTCMKTS:CYDY) is a clinical-stage biotechnology company dedicated to the development and commercialization of innovative therapies targeting serious and life-threatening diseases. The company’s principal focus centers on leronlimab (PRO 140), a humanized monoclonal antibody designed to block the CCR5 receptor, a cellular entry point exploited by HIV and implicated in various other disease processes. By selectively inhibiting CCR5, leronlimab aims to reduce viral load in HIV-infected patients and modulate immune cell trafficking in conditions such as COVID-19, certain cancers, and graft-versus-host disease.
Leronlimab has been investigated in multiple clinical trials worldwide, including studies assessing its potential to restore immune homeostasis in severely ill COVID-19 patients and its role as an adjunct therapy in metastatic breast cancer. The antibody’s subcutaneous administration offers a convenient dosing regimen for long-term treatment, and its safety profile has been examined through Phase 2 and Phase 3 trials. CytoDyn continues to expand its pipeline by exploring leronlimab’s impact on inflammatory pathways and vascular dysfunction, positioning the therapy as a versatile candidate across several therapeutic areas.
Founded in 1992 under the name AnorMED Inc. and later rebranded as CytoDyn in 2011, the company is headquartered in Vancouver, Washington. Throughout its history, CytoDyn has maintained a commitment to advancing monoclonal antibody technology, establishing manufacturing partnerships to ensure scalable production and securing intellectual property rights across multiple jurisdictions. Its clinical research programs have extended to North America, Europe, and South Africa, reflecting a global approach to patient recruitment and regulatory engagement.
Under the leadership of President and Chief Executive Officer Nader Pourhassan, CytoDyn has navigated complex clinical and regulatory landscapes to bring leronlimab closer to potential market approval. The company collaborates with academic institutions, contract research organizations, and strategic partners to optimize trial designs and accelerate development timelines. As CytoDyn advances toward pivotal data readouts, it remains focused on achieving broad patient access to its investigational therapies and on contributing to the growing field of immune-modulating biologics.
